Business Description
Xtacy Therapeutics Corp
NAICS : 525990
SIC : 7129
ISIN : CA98423G1072
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -0.96 | |||||
Debt-to-Equity | -0.05 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -170.31 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47.7 | |||||
3-Year EBITDA Growth Rate | 21.3 | |||||
3-Year EPS without NRI Growth Rate | 21.3 | |||||
3-Year FCF Growth Rate | 20.6 | |||||
3-Year Book Growth Rate | 27 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.48 | |||||
9-Day RSI | 29.77 | |||||
14-Day RSI | 36.48 | |||||
6-1 Month Momentum % | -10.56 | |||||
12-1 Month Momentum % | -79.53 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.13 | |||||
Quick Ratio | 0.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.4 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.83 | |||||
Operating Margin % | -970.69 | |||||
Net Margin % | -337.93 | |||||
FCF Margin % | -125.58 | |||||
ROA % | -62.18 | |||||
ROIC % | -212.45 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 25 | |||||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -2.63 | |||||
EV-to-Revenue | 25.5 | |||||
EV-to-FCF | -19.46 | |||||
Earnings Yield (Greenblatt) % | -38.02 | |||||
FCF Yield % | -5.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:XTCYF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Xtacy Therapeutics Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.043 | ||
EPS (TTM) ($) | -0.003 | ||
Beta | -0.42 | ||
Volatility % | 277.16 | ||
14-Day RSI | 36.48 | ||
14-Day ATR ($) | 0.000897 | ||
20-Day SMA ($) | 0.0288 | ||
12-1 Month Momentum % | -79.53 | ||
52-Week Range ($) | 0.0068 - 0.21 | ||
Shares Outstanding (Mil) | 58.16 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xtacy Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xtacy Therapeutics Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Xtacy Therapeutics Corp Frequently Asked Questions
What is Xtacy Therapeutics Corp(XTCYF)'s stock price today?
When is next earnings date of Xtacy Therapeutics Corp(XTCYF)?
Does Xtacy Therapeutics Corp(XTCYF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |